<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00428246</url>
  </required_header>
  <id_info>
    <org_study_id>0510-04</org_study_id>
    <nct_id>NCT00428246</nct_id>
  </id_info>
  <brief_title>Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation</brief_title>
  <official_title>Anti-Inflammatory and Endothelial Protectant Effects of Paricalcitol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is about possible protective effects of paricalcitol (Zemplar) upon inflammation,
      blood pressure and kidney function. Kidney Inflammation occurs when white blood cells become
      abnormally stimulated and accumulate in the kidney and cause damage to the kidney. The
      purpose of this study is to determine if paricalcitol helps improve kidney injury, blood
      pressure control and kidney function in patients with chronic kidney disease. The study will
      last about 7 weeks and involves about 8 visits to the medical center.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that use of paricalcitol in patients with chronic kidney disease will lead to
      improvement in oxidative stress, inflammation, endothelial function and subsequently
      ambulatory blood pressures and glomerular filtration rate. We will pursue our hypothesis by
      the three specific aims:

      Aim 1: To compare oxidative stress markers in patients treated with paricalcitol before and
      after the study. Aim 2: To measure endothelial function by flow mediated dilation in patients
      with chronic kidney disease before and after paricalcitol. Aim 3: To measure actigraphy
      guided ambulatory blood pressure and GFR in the absence of changes in anti-hypertensive
      medications in patients with chronic kidney disease.

      The study will be double blind randomized pilot trial in 24 patients with chronic kidney
      disease with 1:1:1 allocation to paricalcitol 1 microgram: paricalcitol 2 microgram: Placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-Inflammatory Effects of Paricalcitol</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial Protectant Effects of Paricalcitol</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Paricalcitol on Hypertension</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Paricalcitol on Kidney Function</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Endothelial Dysfunction</condition>
  <condition>Inflammation</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 mcg paricalcitol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 mcg paricalcitol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paricalcitol</intervention_name>
    <description>1 mcg or 2 mcg for 4 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Zemplar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic kidney disease with estimated GFR of 30 mL/minute or more.

          -  Patients receiving stable dose of ACE inhibitor or Angiotensin receptor blockers for
             at least one month.

          -  Patients not currently hypertensive more than 180/110 mmHg by clinic blood pressure.

          -  Hemoglobulin A1C&lt; 11%

        Exclusion Criteria:

          -  Patients taking vitamin D analogs

          -  Calcium&gt; 10 mg/dL

          -  Phosphorus&gt;6 mg/dL

          -  Patients with anticipated need of dialysis in the next 6 weeks

          -  Patients unstable in the opinion of the investigator

          -  Patients who have emergent need for starting IV iron

          -  Patients who will be started on statins within the next 6 weeks

          -  Patients currently taking PDE5 inhibitors

          -  Patients allergic to radiocontrast, Zemplar or who can not take nitroglycerin

          -  Patients known to be HIV positive

          -  Patients who can not give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajiv Agarwal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Richard A. Rodebush VA Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension. 2008 Aug;52(2):249-55. doi: 10.1161/HYPERTENSIONAHA.108.113159. Epub 2008 Jul 7.</citation>
    <PMID>18606901</PMID>
  </results_reference>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2007</study_first_submitted>
  <study_first_submitted_qc>January 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2007</study_first_posted>
  <results_first_submitted>April 6, 2009</results_first_submitted>
  <results_first_submitted_qc>April 6, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 3, 2009</results_first_posted>
  <last_update_submitted>April 6, 2009</last_update_submitted>
  <last_update_submitted_qc>April 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2009</last_update_posted>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Hypertension</keyword>
  <keyword>paricalcitol</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Glomerular filtration rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>169 patients screened from renal speciality clinics from November 2006 to June 2007</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1</title>
          <description>1 mcg paricalcitol</description>
        </group>
        <group group_id="P2">
          <title>2</title>
          <description>2 mcg paricalcitol</description>
        </group>
        <group group_id="P3">
          <title>3</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1</title>
          <description>1 mcg paricalcitol</description>
        </group>
        <group group_id="B2">
          <title>2</title>
          <description>2 mcg paricalcitol</description>
        </group>
        <group group_id="B3">
          <title>3</title>
          <description>Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.6" spread="9.1"/>
                    <measurement group_id="B2" value="67.5" spread="9.1"/>
                    <measurement group_id="B3" value="68.4" spread="12.4"/>
                    <measurement group_id="B4" value="68.4" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-Inflammatory Effects of Paricalcitol</title>
        <description>change in hsCRP level from baseline to 4 weeks</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1</title>
            <description>1 mcg paricalcitol</description>
          </group>
          <group group_id="O2">
            <title>2</title>
            <description>2 mcg paricalcitol</description>
          </group>
          <group group_id="O3">
            <title>3</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Inflammatory Effects of Paricalcitol</title>
          <description>change in hsCRP level from baseline to 4 weeks</description>
          <units>micrograms</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".8" lower_limit=".3" upper_limit="1.9"/>
                    <measurement group_id="O2" value=".5" lower_limit=".3" upper_limit=".9"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.1" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endothelial Protectant Effects of Paricalcitol</title>
        <time_frame>6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Paricalcitol on Hypertension</title>
        <time_frame>6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Paricalcitol on Kidney Function</title>
        <time_frame>6 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1</title>
          <description>1 mcg paricalcitol</description>
        </group>
        <group group_id="E2">
          <title>2</title>
          <description>2 mcg paricalcitol</description>
        </group>
        <group group_id="E3">
          <title>3</title>
          <description>Placebo</description>
        </group>
      </group_list>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rajiv Agarwal</name_or_title>
      <organization>Indiana University</organization>
      <phone>317-988-2241</phone>
      <email>ragarwal@iupui.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

